Nevertheless, targeting LCN2 to blunt post-stroke neuroinflammation may be more advantageous than inhibiting individual cytokines and chemokines because LCN2 is likely an important upstream regulator of these mediators in the inflammatory cascade. This evidence concerns the gene LCN2 and stroke disorder.